• 53% revenue growth to $8.0M in 1H FY26
• Normalised EBITDA of $1.6M at 20% operating margin
• Profit after tax of $1.5M, up from $1.0M loss in 1H FY25

Resonance Health Ltd, a leading provider of medical imaging and clinical trial services, has reported its financial results for the first half of FY26. The company achieved significant revenue growth of 53% to $8.0 million, driven by strong performance across its three business segments: medical imaging, clinical trial services, and software-as-a-medical-device (SaMD). Normalised EBITDA reached $1.6 million, representing a 20% operating margin, and the company returned to profitability with a net profit after tax of $1.5 million, compared to a $1.0 million loss in the prior corresponding period. The company continues to expand its global footprint and addressable markets, with a focus on metabolic diseases, obesity, and liver-related conditions. Key highlights include the execution of major global pharmaceutical clinical trials, the expansion of the TrialsWest clinic network, and the development of new SaMD technologies. Resonance Health maintains its full-year FY26 guidance of revenue of approximately $17 million and EBITDA of $2 million, reflecting the company's disciplined approach to growth and financial management.

Full Year FY26 Guidance: Revenue ~$17M, EBITDA ~$2M

Resonance enters 2H FY26 with continued delivery under global pharmaceutical agreements, a record SaMD order and bid pipeline, expanding and profitable TrialsWest operations, and near-term milestones in fibrosis SaMD development and workflow automation.